A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naive Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Administered By
Awarded By
Contributors
- de Castro III, Carlos Manuel Principal Investigator
Start/End
- March 24, 2017 - October 17, 2017